MENTAL ILLNESS

Higher inflammation and cerebral white matter injury associated with cognitive deficit in asthmatic patients with depression

Yue Lu, MDa, Shu Zhou, MD, PhD, Cunxiu Fan, MD, Jiasi Li, MD, PhD, Yongjie Lian, MD, Yan Shang, MD, PhD, and Xiaoying Bi, MD, PhD

aDepartment of Neurology, Shanghai Changhai Hospital, Shanghai, P.R. China; bDepartment of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, Shanghai, P.R. China

ABSTRACT

Objective: Depression is a common co-morbidity in asthma, worsening asthma control and impairing quality of life. Previous studies have reported a higher risk of cognitive deficit in depression, yet little research has focused on the level of cognition in asthmatic patients with depression. Evidence shows that inflammation may play an important role in both asthma and depression. Cerebral white matter injury, possibly induced by inflammation, has been associated with depression. This study assesses cognitive function in patients with asthma and a depression comorbidity, compared to patients with asthma only or depression only.

Methods: Four groups were studied: Asthma comorbid Depression group (A + D, n = 26), Depression group (D, n = 25), Asthma group (A, n = 33) and Normal controls (N, n = 28). Cognitive function was evaluated using Montreal Cognitive Assessment (MoCA). Inflammatory cytokines were measured, including interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-mobility group box 1 (HMGB1) and Netrin-1. Cerebral white matter injury was assessed by serum myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG), and their correlations with cognitive performance were calculated.

Results: A + D group showed the highest incidence of cognitive deficit, with the cognitive domain particularly affected. Compared to N group, serum levels of IL-6, HMGB1, Netrin-1, MBP and MOG were significantly elevated in A + D group. MOG level negatively correlated with the MoCA score.

Conclusion: Patients with comorbidities presented with more severe cognitive deficits and higher levels of inflammatory cytokines. Cerebral white matter injury may account for the cognitive deficit in patients and MOG could be a potential biomarker for this process.

ARTICLE HISTORY

Received 31 May 2020
Revised 14 November 2020
Accepted 15 November 2020

KEYWORDS

Depression; cognitive deficit; asthma; inflammatory cytokine; cerebral white matter

Introduction

Asthma is a common chronic disease characterized by bronchial hypersensitivity and airway inflammation, resulting in reversible airflow obstruction. An estimated 334 million people worldwide suffer from this disorder, causing a huge burden on society and individuals (1). Evidence has shown that patients with asthma have a 1.52 times higher risk of developing depression as compared to those without asthma, and depressive patients have an increased risk of asthma (2) as compared to those who do not have depression (2). The comorbidity of asthma and depression is associated with poorer symptom control, impairing a patient’s quality of life (3).

Depression, which affects people’s thoughts, emotions, interpersonal relationships and work efficiency, is one of the most common mental disorders and is increasingly recognized as a global public health and social problem (4). Recently, more attention has been paid to the relationship between depression and cognition. Few research studies, however, have focused on the cognitive status of asthmatic patients with depression.

The pathogenetic mechanism of asthma is persistent airway inflammation (5), typically characterized by, but not limited to, atopic response with Th2-predominant inflammation (related to secretion of IL-4, IL-5 and IL-13) (6). Meanwhile, systemic inflammation with neutrophilic
airway inflammation increases in patients with asthma, and is described by increased levels of inflammatory markers such as C-reactive protein (CRP), interleukin-1 (IL-1), tumor necrosis factor- (TNF-)x, and leptin (7). Inflammation also plays a key role in depression. Accumulative studies have described higher levels of inflammatory cytokines in depressive patients (8–10). Moreover, treatment with anti-inflammatory agents, such as selective COX2 inhibitors and TNF antagonists, has been shown to improve symptoms in depressive patients (11). In recent years, new inflammatory cytokines have been investigated in studies for depression.

Our prior research observed that high-mobility group box 1 (HMGB1), along with traditional inflammatory cytokines, such as IL-1β, TNF-x, were elevated in depressive mice (12). HMGB1, remaining at a high level 24h after inflammatory activation and recognized as a late inflammatory mediator (13), has been reported to induce depressive behaviors in mice through neuroinflammation (14). Netrin-1, a new anti-inflammatory factor that plays a critical role in restraining inflammatory respond, was found to promote the proliferation and differentiation of oligodendrocyte precursor cells in favor of myelin recovery, resulting in the repair of cerebral white matter (15).

Given the critical role of inflammation in both asthma and depression, we aimed to seek evidence that inflammation might also be involved in the underlying process of cognitive deficit in the comorbid condition. We also sought to explore the differences in inflammatory cytokines in patients with comorbidity, with asthma alone, and with depression alone.

Immunity diseases targeting white matter, such as multiple sclerosis, have high incidences of depression as well as cognitive deficit (16). Elevated rates of cerebral white matter integrity abnormality on diffusion tensor imaging (DTI) have been reported in depression (17). Our previous research also showed that the serum levels of phospholipids were significantly elevated in patients with post-stroke cognitive deficit, indicating white matter injury (18). We further demonstrated its underlying mechanism, namely that white matter and oligodendrocyte changes driven by inflammatory reaction were associated with depression subsequent to cerebral ischemia (19). Similar results have been observed in other animal models by other researchers (20). These observations developed into a hypothesis that cerebral white matter damage may contribute to cognitive deficit in asthmatic patients with depression.

The present study aimed to assess cognitive function in patients with asthma and depression comorbidity, and to explore the role of inflammation and cerebral white matter injury in cognitive deficit. Furthermore, we attempted to screen for potential biomarkers of cognitive deficit in the comorbid condition and provide effective targets for further treatment.

Methods

Subjects

We recruited four groups of patients from different sources: 26 patients with Asthma comorbid Depression (A+D) (ages 27–70), and 33 Asthma (A) patients (ages 27–70) from the Respiratory Department, Changhai Hospital, Shanghai, China; and 25 Depression (D) patients (ages 24–79 years) from the Psychological Department at the same hospital. Twenty-eight (28) age, sex, and education matched healthy control subjects (N) (ages 40–65 years) were recruited from the general population.

Depression diagnosis was established according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria (21), as assessed by the Structured Clinical Interview for DSM-V and Hamilton Depression Scale (HAMD). The standard Global Initiative for Asthma (GINA) diagnostic criteria (22) were adopted for including the asthma participants. Asthma related information including phenotype, severity assessment (i.e. respiratory function test, asthma control test (ACT)) and detailed therapy was collected for asthmatic patients. None of the patients were on oral corticosteroids therapy. Exclusion criteria included: (1) severe cardiac, hepatic and renal failure, (2) systemic diseases, such as malignant tumors or other neurological diseases leading to brain structural lesions, (3) history of taking psychotic drugs, (4) unable to complete the neuropsychological tests or unwilling to participate in the research.

The study protocol was approved by the local Institutional Research Ethic Committee and performed in compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). All participants completed a written informed consent prior to participation.

Methods

Cognitive assessment

A standard Case Report Form was used to register demographic and medical data. Cognition was
Table 1. Demographic data and cognitive performance in N, D, A and A + D group.

| Variables                        | N      | D      | A      | A + D   | F* or χ² | p value |
|----------------------------------|--------|--------|--------|---------|----------|---------|
| Demographic data                 |        |        |        |         |          |         |
| Age (years)                      | 50.86 (1.43) | 48.36 (2.96) | 47.72 (2.31) | 55.65 (2.28) | 2.419 | 0.070  |
| Gender (female/all)              | 15/28  | 15/25  | 15/33  | 18/26   | 4.240   | 0.236  |
| Education (years)                | 12.64 (0.41) | 12.12 (0.75) | 12.12 (0.54) | 10.50 (0.67) | 2.338 | 0.078  |
| BMI (kg/m²)                      | 24.53 (0.60) | 22.18 (0.64) | 22.75 (0.50) | 23.28 (0.72) | 2.502 | 0.063  |
| Hypertension                     | 3/28   | 7/25   | 4/33   | 5/26    | 3.582   | 0.310  |
| Diabetes                         | 0/28   | 3/25   | 0/33   | 1/26    | 7.119   | 0.057  |
| Smoking                          | 10/28  | 5/25   | 10/33  | 4/26    | 7.525   | 0.058  |
| Drinking                         | 2/28   | 2/25   | 1/33   | 2/26    | 0.845   | 0.872  |
| COPD                             | –      | –      | 8/33   | 5/26    | 0.213   | 0.645  |
| FEV1 (%)                        | –      | –      | 1.86 (0.83) | 2.00 (0.61) | 2.583 | 0.115  |
| FEV1% predicted                  | –      | –      | 69.21 (15.02) | 72.95 (12.42) | 0.252 | 0.618  |
| IgE (IU/ml)                      | –      | –      | 200.44 (96.06) | 244.62 (118.48) | 1.469 | 0.231  |
| FeNO (ppb)                       | –      | –      | 50.19 (39.77) | 74.56 (39.68) | 0.000 | 0.992  |
| Blood eosinophil count           | –      | –      | 3.46 (2.95) | 3.21 (3.96) | 1.888 | 0.177  |
| Asthma phenotype                 | –      | –      | 15/33  | 12/26   | 0.003   | 0.957  |
| Allergic asthma                  | –      | –      | 18/33  | 14/26   | 0.003   | 0.957  |
| Non-allergic asthma              | –      | –      | 20/33  | 17/26   | 0.142   | 0.706  |
| Asthma control test score        | –      | –      | 18.26 (5.14) | 15.56 (6.24) | 1.326 | 0.257  |
| Asthma treatment                 | –      | –      | –      | –       | –       | –      |
| Inhaled corticosteroid           | –      | –      | –      | –       | –       | –      |
| High doses                       | –      | –      | 5/33   | 6/26    | 0.602   | 0.438  |
| Medium doses                     | –      | –      | 28/33  | 23/20   | 0.602   | 0.438  |
| Long-acting β agonist            | –      | –      | 29/33  | 23/26   | 0.005   | 0.945  |
| HAMD score                       | –      | 24.60 (2.81) | –      | 26.62 (4.30) | 2.164 | 0.148  |
| Cognitive performance            |        |        |        |         |          |         |
| MoCA                            | 27.67 (0.26) | 24.32 (0.66) | 24.55 (0.68) | 23.85 (0.61) | 7.495 | <0.001*|
| Naming                          | 3.00 (0.00) | 2.40 (0.18) | 2.64 (0.12) | 2.77 (0.43) | 4.018 | 0.009* |
| Attention                        | 6.00 (0.00) | 5.52 (0.13) | 5.64 (0.12) | 5.35 (0.56) | 5.826 | 0.001* |
| Language                         | 2.79 (0.08) | 2.88 (0.07) | 2.97 (0.03) | 2.50 (0.10) | 8.503 | <0.001*|
| Abstraction                      | 1.67 (0.10) | 0.84 (0.17) | 0.64 (0.13) | 1.15 (0.09) | 12.238 | <0.001*|
| Memory                           | 3.50 (0.20) | 2.92 (0.19) | 2.70 (0.26) | 2.73 (0.22) | 2.489 | 0.064  |
| Orientation                      | 5.92 (0.06) | 5.92 (0.06) | 5.24 (0.16) | 5.35 (0.10) | 9.942 | <0.001*|
| Visuoexecutive                   | 4.63 (0.20) | 3.48 (0.34) | 3.81 (0.18) | 3.85 (0.20) | 4.036 | 0.009* |

Results are shown as mean (±SD); or as frequencies; high-dose was defined as >640 μg/day budesonide or equivalent and medium-dose as ≥320 to ≤640 μg/day budesonide or equivalent.

N, healthy control; D, depression patients; A, asthma patients; A + D, asthma comorbid depression patients; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume 1; IgE, immunoglobulin E; FeNO, fractional exhaled nitric oxide; HAMD, Hamilton Depression Scale; MoCA, Montreal Cognitive Assessment.

*F refers to the ratio of two variances.

Blood samples were collected, centrifuged at 3000 rpm for 15 min, and stored at −80°C until thaw for further analysis. Serum levels of inflammatory cytokines (i.e. IL-1β, IL-6, TNF-α, HMGBl1, Netrin-1, IgE and eosinophil count), as well as cerebral white matter-related indices (i.e. Myelin-basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG)), were assayed using a sandwich enzyme-linked immunosorbent assay (ELISA, Shanghai Westang Biotechnology Company). All measurements were carried out at the same time in the same laboratory and strictly in accordance with the reagent box standard procedure.

Statistical analysis

Group comparisons were performed with a chi-square test for enumeration data (i.e. gender, hypertension, diabetes, smoking, drinking and asthma disease related factors) and with analysis of variance (ANOVA) for measurement data (i.e. cognition score, inflammatory cytokines and white matter-related indices), respectively. The Bonferroni Test was used as a post hoc test to examine the differences between groups when a significant difference across four sample means was revealed. In addition, Spearman correlations were assessed between cerebral white matter evaluated by the Montreal Cognitive Assessment (MoCA) test, a sensitive instrument to measure global cognitive function including naming, attention, language, abstraction, memory and orientation, which is widely accepted for screening mild cognitive impairment. Data were normalized with age and education matched norms, and cognitive deficit was determined by a score of < 26.

Inflammatory cytokines and white matter related indices

Blood samples were collected, centrifuged at 3000 rpm for 15 min, and stored at −80°C until thaw for further analysis. Serum levels of inflammatory cytokines (i.e. IL-1β, IL-6, TNF-α, HMGBl1, Netrin-1, IgE and eosinophil count), as well as cerebral white matter-related indices (i.e. Myelin-basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG)), were assayed using a sandwich enzyme-linked immunosorbent assay (ELISA, Shanghai Westang Biotechnology Company). All measurements were carried out at the same time in the same laboratory and strictly in accordance with the reagent box standard procedure.

Statistical analysis

Group comparisons were performed with a chi-square test for enumeration data (i.e. gender, hypertension, diabetes, smoking, drinking and asthma disease related factors) and with analysis of variance (ANOVA) for measurement data (i.e. cognition score, inflammatory cytokines and white matter-related indices), respectively. The Bonferroni Test was used as a post hoc test to examine the differences between groups when a significant difference across four sample means was revealed. In addition, Spearman correlations were assessed between cerebral white matter related indices.
related indices and inflammatory markers. Associations between MoCA score and cerebral white matter related indices/severity of asthma were also tested by correlation analysis.

**Results**

**Demographic data**

Table 1 presents the demographic data for four groups, including age, education, BMI index, gender, hypertension, diabetes, smoking, drinking, COPD history, depression score (HAMD), asthma phenotype, respiratory function test, asthma control condition (ACT), IgE, FeNO, eosinophil counts and therapy. No significant differences were found between groups. Asthmatic patients (i.e., A and A + D groups) were mainly affected by moderate asthma (60% ≤ FEV1% ≤ 79%) and their symptoms were poorly controlled (ACT < 20). Depressive patients (i.e. D and A + D groups) presented moderate depression (20 < HAMD < 35) at the time of study.

**Cognition evaluation**

Cognitive deficit was observed in 13, 15 and 19 patients in D, A and A + D groups respectively, with the A + D group having the highest incidence of impaired cognition (73.08%) and the lowest score. The subtests of various cognitive domains in the MoCA scale revealed significant differences among the four groups, as indicated by the “F” value. The degrees of freedom in the numerator and denominator are 3 and 108, respectively, as follows: $F_{\text{Naming}}(3,108) = 4.018, p = 0.009$; $F_{\text{Attention}}(3,108) = 5.826, p = 0.001$; $F_{\text{Language}}(3,108) = 8.503, p \leq 0.001$; $F_{\text{Abstraction}}(3,108) = 12.238, p \leq 0.001$; $F_{\text{Memory}}(3,108) = 2.489, p = 0.064$; $F_{\text{Orientation}}(3,108) = 9.942, p \leq 0.001$; $F_{\text{Visuoexecutive}}(3,108) = 4.036, p = 0.009$ (Table 1). The post hoc analyses showed that compared with the N group, the A + D group performed worse in overall MoCA score ($p < 0.001$), attention ($p < 0.001$), language ($p = 0.006$), abstraction ($p = 0.007$), orientation ($p = 0.001$) and visuospatial executive function ($p = 0.023$). In contrast to the D group, performance of the A + D group was better on naming ($p = 0.036$), while poorer on language ($p < 0.001$) and orientation ($p = 0.006$). Compared to the A group, the A + D group showed a significantly lower score for language ($p < 0.001$) and a significantly higher score for abstraction ($p = 0.004$).

**Inflammatory cytokines**

Variance analyses showed significant differences in IL-6, HMGB1 and Netrin-1 among the four groups ($F_{\text{IL-1β}}(3,108) = 0.791, p = 0.502$; $F_{\text{IL-6}}(3,108) = 9.630, p < 0.001$; $F_{\text{TNF-α}}(3,108) = 0.161, p = 0.922$; $F_{\text{HMGB1}}(3,108) = 4.495, p = 0.005$; $F_{\text{Netrin1}}(3,108) = 13.258, p < 0.001$). The post hoc analyses showed that compared with the N group, the A + D group showed a significantly lower score for language ($p < 0.001$) and a significantly higher score for abstraction ($p = 0.004$).
hoc analyses showed that IL-6 increased significantly in the A+D group compared to the N group (p < 0.001), D group (p = 0.044), and A group (p = 0.0027). Similar results were observed for HMGB1, which was significantly elevated in the A+D group versus the N group (p = 0.041). In contrast to the N and A groups, the A+D group showed a significantly increased Netrin-1 level (p = 0.04, p < 0.001) (Figure 1).

Cerebral white matter related indices

As shown in Figure 2, ANOVA results showed a significant difference between groups in MBP and MOG ($F_{MBP(3,108)}$=9.743, p < 0.001; $F_{MOG(3,108)}$=13.714, p < 0.001). Post hoc analyses revealed that MBP was significantly higher in the A+D group than in N (p = 0.0214) and A groups (p < 0.001). MOG was significantly enhanced in the A+D group compared with the other three groups (p < 0.001).

Association between cerebral white matter related indices and inflammatory markers

Table 2 shows the correlation coefficients between cerebral white matter related indices (i.e. MBP and MOG) and the peripheral inflammatory markers (i.e. IL-1β, IL-6, TNF-α, HMGB1, Netrin-1, eosinophil and IgE) in the A+D group. Significant correlation was found between TNF-α and MBP ($r = 0.525$, $P = 0.008$). However, there was no significant correlation between other white matter related indices and inflammatory markers.

Correlation related to MoCA score

In order to screen a sensitive biomarker for cognitive deficit in depression, we conducted the Spearman correlation analysis within the A+D group between the MoCA score and the peripheral serum indices, which showed significant between-group variance (i.e. IL-6, HMGB1, Netrin-1, MBP and MOG). We observed a negative correlation between the MoCA score and MOG ($r = -0.476$, $P = 0.014$, Figure 3) in the A+D group, indicating that white matter injury revealed by elevated MOG could imply a cognitive deficit in patients with comorbidity. However, no significant correlation was found between MoCA and MOG in the N, D, and A group. In addition, inflammatory indices were not correlated with MoCA score in all groups.

Discussion

The present study demonstrated impaired cognitive performance, as well as elevated inflammatory cytokines (IL-6, HMGB1, Netrin-1) in patients with asthma and depression comorbidity. Moreover, we found a significant elevation in white matter lesion-related indices (MBP, MOG), one of which negatively correlated with cognitive performance. These findings provide important evidence on the potential mechanism of cognitive deficit in asthmatic patients with depression.

Existing studies have recognized cognitive burden in patients with asthma (23). Specifically, asthma has a strong effect, not only on broader capacities...
involving academic achievement and global intellect, but also on particular cognitive domains, such as processing speed, executive function, attention, visuospatial functioning, language, learning, and memory (24). However, there is little research on cognition in patients with asthma and depression comorbidity. Our preliminary investigation showed that the A+D patients presented higher incidence of cognition deficit compared to patients with single asthma or depression and healthy controls. The particularly vulnerable cognition domains included attention, language, abstraction, orientation, visuospatial and executive function. The vulnerability of specific cognitive domains remains to be verified with more delicate neuropsychological assessments, and its underlying mechanism needs to be further explored.

Alterations in the immune systems are very likely to contribute to the increased risk of co-occurrence of asthma and depression (25). One study reported an elevated CRP level in children and adolescents with both diseases (26). Another study on gene expression of blood CD4+ T cells from comorbid patients showed that the main active pathways in depressive asthma are IL-6 and CRP signaling (27). In our study, the acute inflammatory mediator IL-6 was elevated significantly in the A+D group. This finding partly aligns with a previous meta-analysis illustrating that concentrations of cytokines, such as IL-1, IL-4, IL-6, TNF-α, were higher in depressive patients than in non-depressive controls (2). Furthermore, we discovered a significant increase in HMGB1 and Netrin-1 in A+D patients. HMGB1 has been shown to be involved in the diseases characterized by chronic inflammation, especially in pulmonary pathology (28), and is elevated in the depressive animal models established for chronic stress (29). Considering that asthma comorbid with depression could be a chronic inflammatory reaction, it would be reasonable to find increased HMGB1 in patients with both diseases.

As a new anti-inflammatory factor, Netrin-1 is expressed in both acute and chronic inflammatory response. Considerable numbers of studies have demonstrated that Netrin-1 plays a role in acute inflammation, such as acute lung injury or pancreatitis by restraining inflammatory damage (30,31). Interestingly, we also found elevated Netrin-1 in asthma patients with depression. A possible explanation is that the chronic inflammatory response in the A+D group may induce a simultaneous process of compensatory protective reaction. Therefore, IL-6, HMGB1 and Netrin-1 may be sensitive indices that reflect the activation of multiple inflammatory pathways in comorbid asthma and depression.

As cerebral white matter-related indices maintain the structure and function of myelin in the central nervous system (CNS), MBP and MOG have been reported to increase significantly in the peripheral blood of depressive individuals (32,33). To our knowledge, there is still a lack of data on the alterations in white matter-related markers in asthma patients. Our study showed that both MBP and MOG increased significantly only in patients with asthma and depression comorbidity, similar to the findings in patients with depression. This may indicated that MBP and MOG were more affected by asthma-induced depression, but not by pathophysiological reaction of asthma itself. We assumed that asthma may induce depression by certain triggers (i.e. stress, systematic inflammation, etc), and the increase of MBP and MOG could be a manifestation of depression related pathophysiological process. The relationship between inflammation and white matter has been largely explored. In the present research, we found that TNF-α was associated with MBP in the A+D group, indicating that the type-1 inflammation, rather than the type-2 inflammation, could be more related to white matter injury. Our previous work (34), as well as other research (35), has

**Table 2. Association between white matter related indices and inflammatory markers in the A+D group.**

|        | IL-1β  | IL-6 | TNF-α | HMGB1 | Netrin-1 | Eosinophil | IgE |
|--------|--------|------|-------|-------|----------|------------|-----|
| MBP    | R      | –0.059 | –0.173 | 0.525 | 0.15 | 0.349 | 0.229 | 0.012 |
|        | P      | 0.785 | 0.42 | 0.008 | 0.466 | 0.087 | 0.332 | 0.954 |
| MOG    | R      | 0.283 | –0.129 | 0.31 | 0.184 | 0.096 | –0.137 | –0.144 |
|        | P      | 0.181 | 0.549 | 0.141 | 0.389 | 0.654 | 0.588 | 0.503 |

A+D, asthma comorbid depression patients; IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; HMGB1, high-mobility group box 1; IgE, immunoglobulin E; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein.

**Figure 3.** Correlation between MoCA score and MOG in the A+D group by Spearman’s analysis.
demonstrated that systemic inflammation could alter the development of white matter by blocking the maturation process of oligodendrocytes through changing the coordinated expression of several transcription factors. Given the above empirical evidence, our results of elevated MBP and MOG may suggest an important pathophysiological alteration in asthma and depression comorbidity, that is, white matter damage.

Furthermore, our study showed that cognitive deficit was negatively correlated with MOG, indicating that white matter lesions may result in cognitive alteration in asthmatic patients with depression. This result was consistent with a previous imaging study, showing a negative correlation between cognition, depressive syndrome and white matter hyperintensities (36). A recent DTI study further illustrated that MOG correlated positively with white matter damage in depression (33). Despite a minor component of myelin sheath (0.01–0.05% of the membrane protein) compared to MBP (30% of the membrane protein) (37). MOG has been exclusively expressed in oligodendrocytes in the CNS (38). MBP, however, was found to additionally express in the peripheral nervous system and cells of the immune system (39). We hypothesize that MOG may be a more specific index than MBP to reflect CNS myelin injury in brain, and therefore, could be a more sensitive biomarker of cognitive deficit in asthma patients with comorbid depression.

The present study has some limitations. First, this is a cross-sectional study, and therefore is unable to determine a causal relationship between cognitive deficits and inflammation or white matter injury. Indeed we included a relatively small sample size which limited the statistical power of the present study. It would be of greater value to investigate the emotion and cognition alterations in a larger number of patients with different severity of asthma and in a follow-up observation cohort. Nevertheless, we observed a phenomenon, which could provide a clue on this relationship. Further research is needed to elucidate its potential mechanism. Second, we performed only the MoCA test as an assessment tool of cognition, which is used routinely as a screen test for mild cognitive deficit. Complete and detailed neuropsychological assessments are encouraged, such as the Wechsler Intelligence Scale and other cognition battery tests, which evaluate multiple cognitive domains. Third, we provided evidence of white matter injuries by means of serum markers, but there is a lack of structural or functional image findings. More research using advanced neuroimaging technic is needed to explore the unique characteristics of white matter injury in the asthma and depression comorbid condition.

Conclusion

The present study identified a high incidence of cognitive deficit and inflammatory cytokine levels in patients with asthma and depression comorbidity. Cognitive deficit was not directly affected by the severity of asthma. Cerebral white matter injuries characterized by increased levels of MOG could be a potential biomarker of this process.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Funding

The work is supported by the National Natural Science Foundation of China (8157050742).

References

1. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 2018;391(10122):783–800. doi:10.1016/S0140-6736(17)33311-1.
2. Jiang MD, Ping Q, Xu Y. Comorbidity between depression and asthma via immune-inflammatory pathways: a meta-analysis. J Affect Disord 2014;166: 22–29. doi:10.1016/j.jad.2014.04.027.
3. Li Y, Jiang Q, Ji Y, Cao C. Anxiety and depression may associate with poorer control and quality of life in adults with asthma. Allergy 2020;75(7):1759–1762. doi:10.1111/all.14189.
4. Ormel J, Cuijpers P, Jorm AF, Schoevers R. Prevention of depression will only succeed when it is structurally embedded and targets big determinants. World J Psychiatry 2019;18(1):111–112. doi:10.1002/wps.20580.
5. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, et al. Dementia prevention, intervention, and care. Lancet 2017; 390(10113): 2673–2734. doi:10.1016/S0140-6736(17)31363-6.
6. Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry 2015;172(4):323–334. doi:10.1176/appi.ajp.2014.14070878.
7. Barnig C, Frossard N, Levy BD. Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther 2018;186:98–113. doi:10.1016/j.pharmthera.2018.01.004.
8. Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev...
9. Wood LG, Baines KJ, Fu J, Scott HA, Gibson PG. The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. Chest 2012;142(1):86–93. doi:10.1378/chest.11-1838.

10. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016;16(1):22–34. doi:10.1038/nri.2015.5.

11. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65(9):732–741. doi:10.1016/j.biopsych.2008.11.029.

12. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27(1):24–31. doi:10.1016/j.it.2005.11.006.

13. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70(1):31–41. doi:10.1001/jamapsychiatry.4.

14. Du BY, Li HL, Zheng HW, et al. Minocycline ameliorates depressive-like behavior and demyelination induced by transient global cerebral ischemia by inhibiting microglial activation. Front Pharmacol 2019;10:1247. doi:10.3389/fphar.2019.01247.

15. Wu T-Y, Liu L, Zhang W, Zhang Y, Liu Y-Z, Shen X-L, Gong H, Yang Y-Y, Bi X-Y, Jiang C-L, et al. High-mobility group box 1 was released actively and involved in LPS induced depressive-like behavior. J Psychiatr Res 2015;64:99–106. doi:10.1016/j.jpsychires.2015.02.016.

16. Lian Y-J, Gong H, Wu T-Y, Su W-J, Zhang Y, Yang Y-Y, Peng W, Zhang T, Zhou J-R, Jiang C-L, et al. Ds-HMGB1 and r-HMGB induce depressive behavior through neuroinflammation in contrast to nonoxid-HMGB1. Brain Behav Immun 2017;59:322–332. doi:10.1016/j.bbi.2016.09.017.

17. He X, Li Y, Lu H, Zhang Z, Wang Y, Yang GY. Netrin-1 overexpression white matter repair and remodeling after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2013;33(12):1921–1927. doi:10.1038/jcbfm.2013.150.

18. Kalron A, Aloni R, Allali G. The relationship between depression, anxiety and cognition and its paradoxical impact on falls in multiple sclerosis patients. Mult Scler Relat Disord 2018;25:167–172. doi:10.1016/j.msard.2018.07.029.

19. Vlasova RM, Siddarth P, Krause B, Leaver AM, Laird KT, St Cyr N, Narr KL, Lavretsky H. Resilience and white matter integrity in geriatric depression. Am J Geriatr Psychiatry 2018;26(8):874–883. doi:10.1016/j.jgp.2018.04.004.

20. Liu M, Zhou K, Li H, Dong X, Tan G, Chai Y, Wang W, Bi X. Potential of serum metabolites for diagnosing post-stroke cognitive impairment. Mol Biosyst 2015;11(12):3287–3296. doi:10.1039/c5mb00470e.

21. Bi X, Zhang Y, Yan B, Fang S, He J, Zhang D, Zhang Z, Kong J, Tan Q, Li X-M, et al. Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice. J Neurochem 2012;123(1):14–20. doi:10.1111/j.1471-4159.2012.07883.x.

22. Miyamoto N, Tanaka R, Shimura H, Watanabe T, Mori H, Onodera M, Mochizuki H, Hattori N, Urabe T. Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain. J Cereb Blood Flow Metab 2010;30(2):299–310. doi:10.1038/jcbfm.2009.210.

23. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013:123–188.

24. Global Initiative for Asthma. Global strategy for asthma management and prevention; 2018. Available from: www.ginasthma.org. Accessed 13 Apr 2019.

25. Caldera-Alvarado G, Khan DA; Defina LF, Prier A, Brown ES. Relationship between asthma and cognition: the Cooper Center Longitudinal Study. Allergy 2013;68(4):545–548. doi:10.1111/all.12125.

26. Irani F, Barbone JM, Beausoleil J, Gerald L. Is asthma associated with cognitive impairments? A meta-analytic review. J Clin Exp Neuropsychol 2017;39(10):965–978. doi:10.1080/13803395.2017.1288802.

27. Van Lieshout RJ, Bienenstock J, MacQueen GM. A review of candidate pathways underlying the association between asthma and major depressive disorder. Psychosom Med 2009;71(2):187–195. doi:10.1097/PSY.0b013e3181907012.

28. Shanahan L, Copeland WE, Worthman CM, Angold A, Costello EF. Children with both asthma and depression are at risk for heightened inflammation. J Pediatr 2013;163(5):1443–1447. doi:10.1016/j.jpeds.2013.06.046.

29. Wang T, Ji Y-L, Yang Y-X, Xiong X-Y, Wang I-M, Sandford AJ, Liang Z-A, He J-Q. Transcriptomic profiling of peripheral blood CD4+ T-cells in asthmatics with and without depression. Gene 2015;565(2):282–287. doi:10.1016/j.gene.2015.04.029.

30. Imbalzano E, Quartuccio S, Di Salvo E, Crea T, Casciaro M, Gangemi S. Association between HMGB1 and asthma: a literature review. Clin Mol Allergy 2017;15:12. doi:10.1186/s12948-017-0068-1.

31. Wang B, Lian Y-J, Su W-J, Peng W, Dong X, Liu L-L, Gong H, Zhang T, Jiang C-L, Wang Y-X, et al. HMGB1 mediates depressive behavior induced by chronic stress through activating the kynurenine pathway. Brain Behav Immun 2018;72:51–60. doi:10.1016/j.bbi.2017.11.017.

32. Mirakaj V, Gatifoud D, Pöttsch C, König K, Rosenberger P. Netrin-1 signaling dampens inflammatory peritonitis. J Immunol 2011;186(1):549–555. doi:10.4049/jimmunol.1002671.

33. Mirakaj V, Thix CA, Laucher S, Mielke C, Morote-Garcia JC, Schmit MA, Henes J, Unertl KE, Köhler D, Rosenberger P. Netrin-1 dampens pulmonary inflammation during acute lung injury. Am J Respir Crit
34. Pusic AD, Mitchell HM, Kunkler PE, Klauer N, Kraig RP. Spreading depression transiently disrupts myelin via interferon-gamma signaling. Exp Neurol 2015;264:43–54. doi:10.1016/j.expneurol.2014.12.001.

35. Wu F, Kong L, Zhu Y. The influence of myelin oligodendrocyte glycoprotein on white matter abnormalities in different onset age of drug-naive depression. Front Psychiatry 2018;9:186. doi:10.3389/fpsyt.2018.00186.

36. Bi X, Yan B, Fang S, Yang Y, He J, Li X-M, Kong J. Quetiapine regulates neurogenesis in ischemic mice by inhibiting NF-kappaB p65/p50 expression. Neurol Res 2009;31(2):159–166. doi:10.1179/174313209X393573.

37. Favrais G, van de Looij Y, Fleiss B, Ramanantsoa N, Bonnin P, Stoltenburg-Didinger G, Lacaud A, Saliba E, Dammann O, Gallego J, et al. Systemic inflammation disrupts the developmental program of white matter. Ann Neurol 2011;70(4):550–565. doi:10.1002/ana.22489.

38. Wolfson L, Wakefield DB, Moscufo N, Kaplan RF, Hall CB, Schmidt JA, Guttmann CRG, White WB. Rapid buildup of brain white matter hyperintensities over 4 years linked to ambulatory blood pressure, mobility, cognition, and depression in old persons. J Gerontol A Biol Sci Med Sci 2013;68(11):1387–1394. doi:10.1093/gerona/glt072.

39. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. J Neurochem 1989;52(1):296–304. doi:10.1111/j.1471-4159.1989.tb10930.x.